An Open Label, Randomized, Multicenter, Comparative, Parallel Group Study of Rebif 44 Mcg Administered Three Times Per Week by Subcutaneous Injection, Compared With Avonex 30 Mcg Administered Once Per Week by Intramuscular Injection in the Treatment of Relapsing-remitting Multiple Sclerosis

Trial Profile

An Open Label, Randomized, Multicenter, Comparative, Parallel Group Study of Rebif 44 Mcg Administered Three Times Per Week by Subcutaneous Injection, Compared With Avonex 30 Mcg Administered Once Per Week by Intramuscular Injection in the Treatment of Relapsing-remitting Multiple Sclerosis

Completed
Phase of Trial: Phase III

Latest Information Update: 17 Sep 2016

At a glance

  • Drugs Interferon beta-1a (Primary) ; Interferon beta-1a
  • Indications Multiple sclerosis
  • Focus Therapeutic Use
  • Acronyms EVIDENCE
  • Sponsors EMD Serono
  • Most Recent Events

    • 24 Sep 2015 Post hoc results will be presented at ECTRIMS 2015, as per EMD Serono media release.
    • 21 May 2015 Results will be presented at the 2015 Annual Meeting of the Consortium of Multiple Sclerosis Centers (CMSC), as reported by EMD Sereno media release.
    • 27 Apr 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top